Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 56 of the 59 references it cites were found in a registry or an index; 30 of the 47 sources its claims cite were checked for support.

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Open access

Abstract

BACKGROUND: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atherosclerotic cardiovascular disease. None of the trials recruiting patients with and without diabetes were designed to assess outcomes separately in patients without diabetes. METHODS: We did a systematic review and meta-analysis of SGLT2 inhibitor trials. We searched the MEDLINE and Embase databases for trials published from database inception to Sept 5, 2022. SGLT2 inhibitor trials that were double-blind, placebo-controlled, performed in adults (age ≥18 years), large (≥500 participants per group), and at least 6 months in duration were included. Summary-level data used for analysis were extracted from published reports or provided by trial investigators, and inverse-variance-weighted meta-analyses were conducted to estimate treatment effects. The main efficacy outcomes were kidney disease progression (standardised to a definition of a sustained ≥50% decrease in estimated glomerular filtration rate [eGFR] from randomisation, a sustained low eGFR, end-stage kidney disease, or death from kidney failure), acute kidney injury, and a composite of cardiovascular death or hospitalisation for heart failure. Other outcomes were death from cardiovascular and non-cardiovascular disease considered separately, and the main safety outcomes were ketoacidosis and lower limb amputation. This study is registered with PROSPERO, CRD42022351618. FINDINGS: ). Compared with placebo, allocation to an SGLT2 inhibitor reduced the risk of kidney disease progression by 37% (relative risk [RR] 0·63, 95% CI 0·58-0·69) with similar RRs in patients with and without diabetes. In the four chronic kidney disease trials, RRs were similar irrespective of primary kidney diagnosis. SGLT2 inhibitors reduced the risk of acute kidney injury by 23% (0·77, 0·70-0·84) and the risk of cardiovascular death or hospitalisation for heart failure by 23% (0·77, 0·74-0·81), again with similar effects in those with and without diabetes. SGLT2 inhibitors also reduced the risk of cardiovascular death (0·86, 0·81-0·92) but did not significantly reduce the risk of non-cardiovascular death (0·94, 0·88-1·02). For these mortality outcomes, RRs were similar in patients with and without diabetes. For all outcomes, results were broadly similar irrespective of trial mean baseline eGFR. Based on estimates of absolute effects, the absolute benefits of SGLT2 inhibition outweighed any serious hazards of ketoacidosis or amputation. INTERPRETATION: In addition to the established cardiovascular benefits of SGLT2 inhibitors, the randomised data support their use for modifying risk of kidney disease progression and acute kidney injury, not only in patients with type 2 diabetes at high cardiovascular risk, but also in patients with chronic kidney disease or heart failure irrespective of diabetes status, primary kidney disease, or kidney function. FUNDING: UK Medical Research Council and Kidney Research UK.

Overview

CoChat Summary

TL;DR

In a collaborative meta-analysis of 13 large placebo-controlled SGLT2 inhibitor trials including 90,409 participants, SGLT2 inhibitors reduced kidney disease progression by 37% and acute kidney injury by 23%, with similar relative effects in patients with and without diabetes. Cardiovascular death or heart failure hospitalisation was reduced by 23%, and absolute benefits outweighed serious hazards of ketoacidosis or amputation in the studied populations.

Key findings

  • Among 90,409 analysed participants (74,804 [82.7%] with diabetes, >99% type 2; 15,605 [17.3%] without diabetes), SGLT2 inhibitors reduced kidney disease progression by 37% overall (RR 0.63, 95% CI 0.58–0.69), with similar RRs in patients with diabetes (0.62, 0.56–0.68) and without diabetes (0.69, 0.57–0.82; heterogeneity p=0.31).
  • SGLT2 inhibitors reduced acute kidney injury by 23% overall (RR 0.77, 95% CI 0.70–0.84), with similar effects in patients with diabetes (0.79, 0.72–0.88) and without diabetes (0.66, 0.54–0.81; heterogeneity p=0.12), and reduced cardiovascular death or hospitalisation for heart failure by 23% (0.77, 0.74–0.81), again similar by diabetes status.
  • Cardiovascular death was reduced by 14% (RR 0.86, 95% CI 0.81–0.92), while non-cardiovascular death was not significantly reduced (0.94, 0.88–1.02); ketoacidosis RR in patients with diabetes was 2.12 (1.49–3.04), and lower limb amputation overall was 1.15 (1.02–1.30), driven by CANVAS, with no significant association in the other 12 trials (1.06, 0.93–1.21).
  • In chronic kidney disease trials, kidney disease progression RRs were similar by primary kidney diagnosis: diabetic kidney disease 0.60 (0.53–0.69), ischaemic/hypertensive kidney disease 0.70 (0.50–1.00), glomerular disease 0.60 (0.46–0.78), and other/unknown 0.74 (0.51–1.08).

Methods

  • Systematic review and meta-analysis; MEDLINE and Embase were searched from database inception to Sept 5, 2022, for double-blind, placebo-controlled SGLT2 inhibitor trials in adults (age ≥18 years), with ≥500 participants per group and ≥6 months duration; 13 trials were included.
  • Summary-level data were extracted from published reports or provided by trial investigators; kidney disease progression was standardised to a sustained ≥50% eGFR decrease from randomisation, sustained low eGFR, end-stage kidney disease, or death from kidney failure, and inverse-variance-weighted meta-analyses estimated treatment effects.
  • Main outcomes were kidney disease progression, acute kidney injury, and cardiovascular death or hospitalisation for heart failure; other outcomes included cardiovascular and non-cardiovascular death, with safety outcomes of ketoacidosis and lower limb amputation; analyses were by diabetes status, primary kidney diagnosis, and trial mean baseline eGFR. PROSPERO registration CRD42022351618.

Limitations

  • Stated in the paper: there were low numbers of cardiovascular deaths and heart failure hospitalisations in patients with chronic kidney disease without diabetes; acute kidney injury adjudication was not performed in most trials; individual participant-level data were not available, precluding detailed eGFR slope analyses; efficacy and safety in dialysis or transplant patients, other kidney diagnoses (e.g., polycystic kidney disease), and type 1 diabetes remain unevaluated; absolute effect estimates are specific to the recruited trial populations.
  • Stated in the paper: some subgroup data were limited, with wide confidence intervals for non-diabetic kidney diagnoses, and ketoacidosis events in patients without diabetes were too few to estimate absolute effects.
  • Evident from the text: the meta-analysis relies on summary-level trial data rather than individual participant data; diabetes status is baseline-defined and >99% of participants with diabetes had type 2 diabetes; outcome definitions varied across trials despite standardisation, and several analyses (e.g., by primary kidney diagnosis, eGFR trend) were exploratory with multiple testing.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)02074-8

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Effect of sodium glucose co-transporter-2 inhibition on kidney disease outcomes by diabetes status Kidney disease progression was defined as a sustained decrease in eGFR (≥50%) from randomisation, a sustained low eGFR, end-stage kidney disease, or death from kidney failure in all presented trials. Outcome definition details for each trial are provided in the appendix (pp 9–11). Rate values are not presented for the combined subtotal and total populations due to the heterogeneity in rates across the individual trials. eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. NA=not available. *One participant without diabetes in DELIVER was missing a baseline creatinine measurement and was excluded.
Figure 1 Effect of sodium glucose co-transporter-2 inhibition on kidney disease outcomes by diabetes status Kidney disease progression was defined as a sustained decrease in eGFR (≥50%) from randomisation, a sustained low eGFR, end-stage kidney disease, or death from kidney failure in all presented trials. Outcome definition details for each trial are provided in the appendix (pp 9–11). Rate values are not presented for the combined subtotal and total populations due to the heterogeneity in rates across the individual trials. eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. NA=not available. *One participant without diabetes in DELIVER was missing a baseline creatinine measurement and was excluded.CC BY · PubMed Central
Figure 2 Effect of sodium glucose co-transporter-2 inhibition on kidney disease progression by presumed primary kidney disease (chronic kidney disease trials only) Effects in IgA nephropathy, focal segmental glomerulosclerosis, and other glomerular diseases considered separately are provided in the appendix (p 18). Rate values are not presented for the combined subtotal and total populations due to the heterogeneity in rates across the individual trials. eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. *RR in the diabetic kidney disease or nephropathy subgroup excluding SCORED (which did not formally assess primary kidney disease) is 0·59 (95% CI 0·52–0·68).
Figure 2 Effect of sodium glucose co-transporter-2 inhibition on kidney disease progression by presumed primary kidney disease (chronic kidney disease trials only) Effects in IgA nephropathy, focal segmental glomerulosclerosis, and other glomerular diseases considered separately are provided in the appendix (p 18). Rate values are not presented for the combined subtotal and total populations due to the heterogeneity in rates across the individual trials. eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. *RR in the diabetic kidney disease or nephropathy subgroup excluding SCORED (which did not formally assess primary kidney disease) is 0·59 (95% CI 0·52–0·68).CC BY · PubMed Central
Figure 3 Effect of sodium glucose co-transporter-2 inhibition on heart failure and mortality outcomes by diabetes status Outcome data sources by trial are provided in the appendix (pp 10–11). Effects on heart failure and mortality were also analysed by trial with event rate per 1000 patient-years presented for each trial (appendix pp 19–20). eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. *Cardiovascular death or hospitalisation for heart failure outcomes exclude urgent heart failure visits. †Data from SOLOIST-WHF are included in totals but excluded from the stable heart failure trials group as the trial included patients with recent acute decompensated heart failure.
Figure 3 Effect of sodium glucose co-transporter-2 inhibition on heart failure and mortality outcomes by diabetes status Outcome data sources by trial are provided in the appendix (pp 10–11). Effects on heart failure and mortality were also analysed by trial with event rate per 1000 patient-years presented for each trial (appendix pp 19–20). eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. *Cardiovascular death or hospitalisation for heart failure outcomes exclude urgent heart failure visits. †Data from SOLOIST-WHF are included in totals but excluded from the stable heart failure trials group as the trial included patients with recent acute decompensated heart failure.CC BY · PubMed Central
Figure 4 Effect of sodium glucose co-transporter-2 inhibition on ketoacidosis and lower limb amputation by diabetes status Effects on ketoacidosis and lower limb amputation were also analysed by trial with event rate per 1000 patient-years presented for each trial (appendix pp 21–22). Total values and forest plots are not presented for ketoacidosis due to the small number of events in patients without diabetes. eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. *Data from SOLOIST-WHF are included in totals but excluded from the stable heart failure trials group as the trial included patients with acute decompensated heart failure. †The hypothesis that SGLT2i might increase the risk of lower limb amputation was first raised by results from the CANVAS trial;21 the subtotal excluding CANVAS therefore reflects the combined results from the independent set of hypothesis-testing trials.
Figure 4 Effect of sodium glucose co-transporter-2 inhibition on ketoacidosis and lower limb amputation by diabetes status Effects on ketoacidosis and lower limb amputation were also analysed by trial with event rate per 1000 patient-years presented for each trial (appendix pp 21–22). Total values and forest plots are not presented for ketoacidosis due to the small number of events in patients without diabetes. eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. *Data from SOLOIST-WHF are included in totals but excluded from the stable heart failure trials group as the trial included patients with acute decompensated heart failure. †The hypothesis that SGLT2i might increase the risk of lower limb amputation was first raised by results from the CANVAS trial;21 the subtotal excluding CANVAS therefore reflects the combined results from the independent set of hypothesis-testing trials.CC BY · PubMed Central
Figure 5 Absolute benefits and harms of SGLT2 inhibition per 1000 patient-years by diabetes status and patient group Patient group specific absolute effects estimated by applying the diabetes subgroup specific RR to the average event rate in the placebo arms (first event only). Negative numbers indicate events avoided by SGLT2 inhibition per 1000 patient-years. Error bars represent SE in the numbers of events avoided or caused, estimated from uncertainty in the RRs. Mean eGFR values are given for combined trial populations by patient group and diabetes status. Placebo population mean event rates are the absolute numbers of events per 1000 patient-years in the placebo groups of all trials in the relevant subpopulation. eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. *Additionally, two (SE 0·5) fewer myocardial infarctions per 1000 patient-years of SGLT2i treatment were observed in the diabetes and high atherosclerotic cardiovascular risk group. †RRs to determine absolute effects for lower limb amputation included CANVAS. ‡Too few ketoacidosis events to estimate absolute effects.
Figure 5 Absolute benefits and harms of SGLT2 inhibition per 1000 patient-years by diabetes status and patient group Patient group specific absolute effects estimated by applying the diabetes subgroup specific RR to the average event rate in the placebo arms (first event only). Negative numbers indicate events avoided by SGLT2 inhibition per 1000 patient-years. Error bars represent SE in the numbers of events avoided or caused, estimated from uncertainty in the RRs. Mean eGFR values are given for combined trial populations by patient group and diabetes status. Placebo population mean event rates are the absolute numbers of events per 1000 patient-years in the placebo groups of all trials in the relevant subpopulation. eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. *Additionally, two (SE 0·5) fewer myocardial infarctions per 1000 patient-years of SGLT2i treatment were observed in the diabetes and high atherosclerotic cardiovascular risk group. †RRs to determine absolute effects for lower limb amputation included CANVAS. ‡Too few ketoacidosis events to estimate absolute effects.CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 1 Not valid · 11 Not checked · 64 Own results and interpretations

55 more claims · 4 with their cited sources checked

Create a free account to see all 87 claims and to verify the 17 references still open.

See all claims — free account
  • It may state two separate claims as one. 18
  • Probably not a substantial claim. 10

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 59 references

Research works printed but not linked: 2

  1. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med (in press).
  2. Deeks, 2019, Chapter 10: Analysing data and undertaking meta-analyses

Cited by

See all 1,020

Metadata

Authors
Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., Staplin, N., Zhu, D., Anker, S. D., Bhatt, D. L., Brueckmann, M., Butler, J., Cherney, D. Z. I., Green, J. B., Hauske, S. J., Haynes, R., Heerspink, H. J. L., Herrington, W. G., Inzucchi, S. E., Jardine, M. J., Liu, C.-C., Mahaffey, K. W., McCausland, F. R., McGuire, D. K., McMurray, J. J. V., Neal, B., Neuen, B. L., Packer, M., Perkovic, V., Sabatine, M. S., Solomon, S. D., Vaduganathan, M., Wanner, C., Wheeler, D. C., Wiviott, S. D., & Zannad, F.
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-11
Volume
400
Issue
10365
Pages
1788-1801
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4308291843
Cited by
1,020
References
59
Citations by year
2026: 157 · 2025: 293 · 2024: 319 · 2023: 242 · 2022: 8
FWCI
30.86
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
Funders
  • Medical Research Council (MR/R007764/1, MC_UU_00017/3, MC_UU_00017/4)
  • Kidney Research UK
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
SGLT2 inhibitors, diabetes mellitus, renal outcomes, chronic kidney disease, acute kidney injury, cardiovascular outcomes, heart failure, estimated glomerular filtration rate decline, end-stage renal disease, cardiovascular mortality, heart failure hospitalization, ketoacidosis, lower limb amputation, non-diabetic patients, drug safety and efficacy
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Adolescent, Adult, Diabetes Mellitus, Type 2, Glucose, Heart Failure, Humans, Ketosis, Kidney, Sodium, Randomized Controlled Trials as Topic, Disease Progression, Sodium-Glucose Transporter 2, Renal Insufficiency, Chronic, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. https://app.cochat.ai/papers/10.1016/s0140-6736(22)02074-8
The paper
Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., Staplin, N., Zhu, D., Anker, S. D., Bhatt, D. L., Brueckmann, M., Butler, J., Cherney, D. Z. I., Green, J. B., Hauske, S. J., . . . Zannad, F. (2022). Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. The Lancet. https://doi.org/10.1016/s0140-6736(22)02074-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.